OccuRx is focused on developing a new class of drugs that target the GPR68 receptor, aiming to address various fibrotic conditions. Their pipeline includes candidate drugs specifically designed for indications such as scleroderma, chronic kidney disease, focal segmental glomerulosclerosis, diabetic nephropathy, and diabetic retinopathy. The company emphasizes the importance of precision medicine, utilizing genetic information and biomarkers to identify patients who are most likely to benefit from their innovative therapeutics. This approach aims to ensure that treatments are tailored to the individual based on their genetic makeup and the specific stage of their disease.

The company has demonstrated promising results in early-phase trials, showing that their lead compound, FT011 (asengeprast), can effectively reverse inflammatory and fibrotic pathways in animal models of chronic kidney disease. This suggests a potential for translating these findings into human applications, as many of the dysregulated molecular pathways observed in animal studies are also present in human diseases. OccuRx's commitment to pioneering science in the field of fibrotic diseases positions them as a key player in developing targeted therapies that could significantly improve patient outcomes.

Australia

OccuRx is a biotechnology company that specializes in developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases.

Endocrine System Diseases

Eye Diseases

Skin Diseases

Urogenital Diseases

OccuRx

Scleroderma

FT011

Small Molecule Pharmaceuticals

Chronic kidney disease

Focal segmental glomerulosclerosis

OCX063

Diabetic retinopathy

Dry eye syndrome

Ocular inflammation

OCX071

Retinal disease

OCX026

Therapeutic

OccuRx

Company Details